Physician profile
David A Glander
NPI 1669476362
$25,440.08
in general payments reported to CMS, 2019-2025
80 companies · $5,234 in 2025
The $5,234 reported for 2025 was more than what 85% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,049 · 2020: $2,082 · 2021: $3,051 · 2022: $3,562 · 2023: $3,828 · 2024: $5,634 · 2025: $5,234.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $15K · Education: $113.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $14,583.34 |
| Education | $113.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,430.21 | 2019-2025 | |
| Ucb, INC. | $1,816.05 | 2019-2025 | Briviact, Nayzilam, Rystiggo |
| Mdd US Operations, LLC | $1,423.14 | 2019-2025 | Apokyn, Apokyn |
| Novartis Pharmaceuticals Corporation | $1,394.06 | 2019-2025 | |
| Biogen, INC. | $1,284.20 | 2019-2025 | Vumerity, Tysabri, Avonex |
| Jazz Pharmaceuticals INC. | $1,027.99 | 2019-2025 | |
| Emd Serono, INC. | $863.86 | 2019-2025 | Mavenclad |
| Alexion Pharmaceuticals, INC. | $812.73 | 2019-2025 | Ultomiris, Soliris |
| Lilly USA, LLC | $730.55 | 2019-2025 | Kisunla, Amyvid, Emgality |
| Vanda Pharmaceuticals INC. | $689.36 | 2021-2025 | Ponvory, Fanapt, Hetlioz |
| Eisai INC. | $647.77 | 2021-2025 | |
| Catalyst Pharmaceuticals, INC. | $641.06 | 2023-2025 | Fycompa, Firdapse |
| Amgen INC. | $637.59 | 2019-2025 | Uplizna, Aimovig |
| Sk Life Science, INC. | $584.45 | 2020-2025 | |
| Supernus Pharmaceuticals, INC. | $581.32 | 2019-2020 |
Show all 80 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Glander listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.